The legal landscape surrounding healthcare competition has undergone a seismic shift as antitrust challenges to antisteering provisions in hospital-insurer contracts have become significantly more frequent and complex over the past twelve months. These contractual clauses, once considered standard boilerplate in the negotiation rooms of major health systems and insurance providers, are now the primary targets of federal regulators, state attorneys general, and private class-action litigants. As of late 2026, the focus on these provisions represents a broader effort by the Department of Justice (DOJ) and the Federal Trade Commission (FTC) to dismantle barriers that prevent price transparency and consumer choice in the healthcare marketplace.
Antisteering and anti-tiering provisions are mechanisms used by dominant hospital systems to prevent insurers from incentivizing patients to seek care at rival facilities. In a typical "steering" scenario, an insurer might create a "tiered" network where patients pay lower out-of-pocket costs to visit high-value, lower-cost providers. Antisteering clauses explicitly forbid this practice, requiring the insurer to treat the dominant hospital system as the most favorable option, regardless of the cost or quality of competitors. While hospitals argue these clauses ensure a steady patient volume necessary to maintain specialized services and care for indigent populations, critics contend they are predatory tools used to insulate high-priced systems from market competition.
The Mechanics of Contractual Restraints
To understand the surge in litigation, one must examine the specific types of "restrictive covenants" currently under fire. Beyond basic antisteering, many contracts include "all-or-nothing" clauses, which require an insurer to include every facility in a hospital system’s network if they want to include even one. When a hospital system is the sole provider of essential services in a specific geography—often referred to as a "must-have" hospital—they can leverage that position to force insurers into accepting these restrictive terms across an entire region or state.
Another common feature is the "most-favored-nation" (MFN) clause, which guarantees that a hospital receives the best rates offered to any other insurer, effectively setting a price floor that prevents smaller, more innovative insurers from negotiating better deals. In the current 2026 legal environment, the intersection of these clauses is being viewed by the courts not as individual contract points, but as a comprehensive strategy to "lock up" a market.
A Chronology of Regulatory and Legal Pressure
The path to the current wave of litigation was paved by several landmark cases and policy shifts over the last decade. Understanding this timeline is essential for contextualizing why 2026 has become a flashpoint for antitrust enforcement.
- 2016: The Carolinas HealthCare System Case: The DOJ and the North Carolina Attorney General filed a civil antitrust lawsuit against Carolinas HealthCare System (now Atrium Health), alleging the system used its market power to impose antisteering restrictions. This case served as the first major signal that federal regulators were scrutinizing these specific contractual behaviors.
- 2019-2021: The Sutter Health Settlement: In one of the most influential cases in healthcare history, Sutter Health in California settled for $575 million following allegations of using its market dominance to drive up prices through "all-or-nothing" and antisteering provisions. This settlement established a blueprint for private litigants and state enforcers.
- 2023: The Executive Order on Promoting Competition: A renewed federal emphasis on healthcare competition led to increased funding for the FTC and DOJ to investigate "monopolistic practices" in hospital consolidations and contracting.
- 2024-2025: State-Level Legislative Action: Several states, including New York and Connecticut, passed laws explicitly banning or severely limiting the use of antisteering and anti-tiering clauses in healthcare contracts, providing a statutory basis for new lawsuits.
- 2026: The Current Surge: The past year has seen a 40% increase in private antitrust filings compared to the 2022-2024 average, largely driven by employers and unions who claim that these provisions have directly led to inflated premiums and restricted benefits for their members.
Supporting Data: The Cost of Restricted Competition
Recent economic data underscores the motivation behind the current litigation. Studies conducted by the Health Care Cost Institute (HCCI) and various academic institutions throughout 2025 and 2026 have highlighted a direct correlation between restrictive contracting and healthcare inflation.
In markets where dominant hospital systems utilize antisteering and anti-tiering clauses, the cost of a standard inpatient stay is, on average, 15% to 22% higher than in more competitive markets with similar demographics. Furthermore, data from the Kaiser Family Foundation indicates that in regions where these clauses are prevalent, employer-sponsored insurance premiums have risen at nearly double the rate of the national average.
Analysis of "must-have" hospital systems reveals that even when lower-cost competitors enter a market, their ability to gain market share is stunted by as much as 60% if the dominant incumbent has antisteering protections in place with the region’s largest insurers. This "market stagnation" is a primary point of contention in the latest round of DOJ filings, which argue that these clauses prevent the natural "creative destruction" necessary for a healthy economy.
Perspectives from the Field: Arguments and Rebuttals
The legal battle lines are clearly drawn, with both sides offering fundamentally different views on the impact of these provisions on the healthcare ecosystem.
The Plaintiff Perspective:
Attorneys representing employer groups and consumer advocates argue that antisteering provisions are a "hidden tax" on American workers. "These are not mere contract negotiations; they are the architectural blueprints of a monopoly," stated Sarah Jenkins, a lead attorney in a pending class-action suit against a major Midwestern health system. "By preventing insurers from rewarding value, these hospitals are effectively punishing efficiency and transparency."
The Hospital Perspective:
Hospital associations and defense counsel maintain that these provisions are essential for integrated care delivery. They argue that "steering" fragments care, as patients may be directed to different facilities for different procedures based solely on cost, rather than clinical continuity. "A hospital system is an ecosystem," a spokesperson for the American Hospital Association noted in a recent brief. "To maintain 24/7 emergency departments, burn units, and neonatal intensive care, we must have a predictable and stable volume of patients across all service lines. These provisions allow for that stability."
The Insurer Dilemma:
Insurers often find themselves in the middle. While they publicly advocate for the ability to steer patients toward high-value providers, many have historically accepted these clauses to ensure their members have access to the dominant "must-have" systems. However, in 2026, more insurers are cooperating with government investigators, providing internal documents that show they were "coerced" into accepting antisteering terms under the threat of being excluded from a hospital’s network entirely.
Broader Implications and the Future of Healthcare Contracting
The outcome of the current wave of litigation will likely redefine the relationship between payers and providers for the next decade. If the courts continue to trend toward viewing antisteering provisions as inherently anticompetitive, we can expect several significant shifts in the industry.
First, there will be a move toward "Value-Based Insurance Design" (VBID). Without the shackles of antisteering clauses, insurers will be free to create more aggressive tiered networks that prioritize providers based on objective quality metrics and transparent pricing. This could lead to a "race to the top" among hospitals competing for Tier 1 status.
Second, the "all-or-nothing" model of hospital systems is likely to crumble. This would force large systems to justify the costs of each individual facility rather than relying on the prestige of their flagship academic medical centers to carry their less efficient community branches.
Third, there is the potential for a "correction" in healthcare pricing. If competition is successfully reintroduced into consolidated markets, some analysts predict a stabilization or even a modest reduction in the growth rate of commercial healthcare prices. However, this comes with the risk of financial instability for some rural or safety-net hospitals that have relied on the cross-subsidization provided by the current system.
As the legal proceedings of 2026 unfold, the healthcare industry is at a crossroads. The transition from a model based on market leverage to one based on competitive value is fraught with legal peril and operational challenges. For Derek Moore and other legal observers, the upcoming rulings in the federal courts will serve as a definitive barometer for the future of antitrust enforcement in the United States. The era of the "unquestioned dominant system" is being challenged, one contract clause at a time.
